Dec 02, 2020 / 01:00PM GMT
Umer Raffat - Evercore ISI Institutional Equities, Research Division - Senior MD & Senior Analyst of Equity Research
Excellent. Well, listen, good morning, guys. Thanks for joining us. Super excited to have Royalty Pharma management join us this morning.
(technical difficulty)
Before we do, Pablo, would love to have you perhaps kick things off and highlight for us the key things high on your priority list as we head into the new year.
Pablo Legorreta - Royalty Pharma plc - Founder, Chairman of the Board & CEO
Of course, Umer. Thank you. And good morning, everyone. It is a pleasure to be here at the Evercore ISI Healthcare Conference. I look forward to talking -- to taking your questions. But first, for those who are less familiar with our company, I thought it would be helpful to spend a few minutes explaining why Royalty Pharma is, not only a different kind of biopharma company, but also a unique investment proposition.
Let me start at the beginning. I founded the company in 1996, having recognized the large untapped
Royalty Pharma PLC at Evercore ISI HealthCONx Conference (Virtual) Transcript
Dec 02, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers